U.S. Interventional Oncology Market (2025 - 2030) Size, Share & Trends Analysis Report By Technique (Ablation Therapies, Embolization Therapies), By Procedure (Tumor Ablation, Tumor Biopsy), By Application, By End Use, And Segment Forecasts

U.S. Interventional Oncology Market Trends

The U.S. interventional oncology market size was estimated at USD 998.4 million in 2024 and is projected to grow at a CAGR of 8.17% from 2025 to 2030. The market is growing due to increasing cancer prevalence, rising technological advancements in minimally invasive procedures, increasing investments in the field of interventional oncology, and the growing geriatric population in the country.

The rising prevalence of cancer in the U.S. is a major factor driving the market growth. According to the American Cancer Society, around. 2,041,910 new cancers are estimated to occur in the U.S. in 2025, while cancer is expected to cause 618,120 mortalities in the same year. As traditional treatments such as chemotherapy and radiation therapy often have significant side effects, minimally invasive alternatives such as radiofrequency ablation and microwave ablation are gaining popularity. These procedures offer localized tumor destruction with minimal damage to surrounding tissues, improving patient outcomes and driving demand for interventional oncology solutions.

Leading Sites of New Cancer Cases and Deaths - 2024 Estimates 

Source: American Cancer Society, Grand View Research Analysis

Continuous technological advancements in interventional oncology are enhancing the effectiveness and adoption of these procedures. Companies operating in the market are focusing on innovation to introduce advanced products in the market, thereby improving patient outcomes. For instance, in September 2023, Profound Medical obtained 510(k) clearance from the U.S. FDA for its TULSA-PRO Thermal Boost module, which allows surgeons to temporarily elevate ablation temperatures in specific areas of the prostate. The Thermal Boost feature has led to improved treatment results in 88% of prostate cancer cases, thereby enhancing both efficacy and workflow efficiency. Such advancements improve clinical outcomes and increase the appeal of interventional oncology among healthcare providers.

The growing investment in interventional oncology from both public and private sectors is accelerating market expansion in the U.S. Government initiatives, research funding, and venture capital investments are supporting the development of innovative treatment modalities to improve precision oncology, ensuring that interventional techniques are integrated into mainstream cancer care. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping for precision-guided interventions for HCC.

Market Concentration & Characteristics

The U.S. interventional oncology industry is characterized by increasing investments, a growing focus on innovation, a supportive regulatory framework, and an evolving competitive landscape. Moreover, the high cancer rates in the U.S., coupled with the aging population, which is significantly vulnerable to various cancers and chronic conditions, further shapes the U.S. interventional oncology industry.

The high degree of innovation in the U.S. interventional oncology industry is driven by the strong demand for minimally invasive procedures, resulting continuous advancements in treatment technologies such as tumor ablation and embolization. For instance, in December 2024, AngioDynamics NanoKnife System received FDA clearance for prostate tissue ablation, following the PRESERVE clinical study. The study demonstrated the system's effectiveness in ablating prostate tissue in intermediate-risk prostate cancer patients, with 84% free from disease at 12 months. It also showed strong quality of life outcomes, preserving urinary continence and erectile function. In addition, private and public sector funding supports the development of novel therapies.

Mergers and acquisitions in the U.S. interventional oncology industry are accelerating. For instance, in February 2025, Teleflex Incorporated revealed a conclusive agreement to purchase nearly all of the Vascular Intervention division of BIOTRONIK SE & Co. KG, pending specific adjustments.This acquisition is expected to significantly improve Teleflex’s Interventional portfolio by including a complete range of vascular intervention devices, such as drug-eluting stents, drug-coated balloons, balloon and self-expanding bare metal stents, covered stents, and balloon catheters in its portfolio.

Regulatory frameworks significantly influence the U.S. interventional oncology industry by shaping product development, approval timelines, and market entry strategies. Stringent regulations imposed by agencies such as the FDA ensure that devices meet safety and efficacy standards, which can delay the introduction of innovative technologies. While these regulations protect patients, they also create barriers for manufacturers, potentially impacting competition and innovation.

The U.S. interventional oncology industry witness’s significant product substitutes due to the rapid advancement of alternative treatment modalities such as systemic therapies, immunotherapies, and radiation treatments. These alternatives can offer comparable efficacy with potentially fewer side effects or less invasive procedures. However, interventional oncology techniques, such as ablation and embolization, offer unique benefits that are not easily available from alternative treatments such as chemotherapy or radiation.

The U.S. interventional oncology industry is witnessing significant regional expansion. Key players are increasing their presence through strategic partnerships and acquisitions, enhancing service offerings and technological capabilities. In addition, favorable reimbursement policies and a well-established healthcare infrastructure support the growth of interventional oncology services across various states. As hospitals and specialty clinics adopt innovative technologies, the opportunities for market players to increase their presence in the country are expected to witness growth.

Technique Insights

Based on techniques, the ablation therapies segment led the market with the largest revenue share of 37.11% in 2024 and is expected to witness at the fastest CAGR over the forecast period. Ablation methods, such as radiofrequency, microwave, cryoablation, and irreversible electroporation, are increasingly recognized as viable alternatives to surgery for patients who cannot undergo resection or systemic treatments. Advances in ablation technology, along with enhancements in imaging techniques such as CT, MRI, and ultrasound, are improving precision, treatment efficacy, and effectiveness of procedures. For instance, in July 2024, Techsomed launched BioTraceIO Vision and BioTraceIO Precision software in the U.S., designed for image-guided ablation therapy. These innovative tools enhance precision in medical procedures, improving patient outcomes by integrating advanced imaging technology with therapeutic applications.

The image-guided therapies segment is expected to witness at a significant CAGR during the forecast period. Investments by hospitals and cancer centers in innovative image-guided procedures are driving the expansion of IGRT-compatible equipment, including high-resolution imaging systems and radiotherapy devices.

Procedures Insights

Based on procedures, the vascular interventions segment led the market with the largest revenue share of 38.18% in 2024. Vascular intervention procedures such as transarterial chemoembolization, transarterial radioembolization, and percutaneous transhepatic biliary drainage are increasingly preferred for their precision in targeting tumors, minimizing systemic toxicity, and enhancing patient outcomes. In addition, innovations such as drug-eluting beads and artificial intelligence integration in procedure planning are further propelling the adoption of vascular interventions.

The tumor ablation segment is expected to witness at the fastest CAGR over the forecast period. Ablation treatment methods, such as radiofrequency ablation, microwave ablation, and cryoablation, serve as alternative first-line therapies for patients with inoperable primary and secondary liver tumors. The increasing efforts by market players to introduce effective tumor ablation therapies fuels the segment growth. For instance, in March 2024, Medtronic received FDA clearance for its OsteoCool 2.0 bone tumor ablation system, designed to treat painful bone tumors. This advanced system utilizes radiofrequency energy to target and destroy tumor cells, enhancing patient comfort and outcomes in oncological care.

Application Insights

Based on application, the liver cancer segment led the market with the largest revenue share of 28.0% in 2024. The rising incidence of liver cancer, especially hepatocellular carcinoma (HCC), is driving segment growth. The American Cancer Society projects 42,240 new cases of liver and intrahepatic bile duct cancer in 2025, with 28,220 men and 14,020 women affected. This increasing prevalence of liver cancer in the country significantly increases the adoption and demand for effective interventional oncology solutions, thereby contributing to the segment growth.

The lung cancer segment is expected to witness at the fastest CAGR over the forecast period. Lung cancer continues to be a major cause of cancer-related mortality, with 124,730 deaths anticipated in 2025-60,540 among women and 64,190 among men, per the American Cancer Society. Procedures such as radiofrequency ablation and cryoablation offer targeted therapies with fewer complications compared to traditional surgery. The demand for such treatments is rising due to their effectiveness and patient preference for less invasive options. As the prevalence of lung cancer increases, the demand for interventional oncology solutions for lung cancer is expected to grow over the forecast period.

End Use Insights

Based on end use, the hospitals segment led the market with the largest revenue share of 55.48% in 2024. This can be attributed to the increasing number of patient visits for cancer treatment and the demand for comprehensive care services. Hospitals offer advanced infrastructure, multidisciplinary expertise, and specialized equipment, such as imaging systems and ablation devices, essential for minimally invasive procedures such as tumor ablation and embolization. These facilities provide integrated care, including diagnosis, treatment, and follow-up, making them attractive to patients.

The specialty clinics segment is expected to grow at the fastest CAGR during the forecast period. These clinics provide personalized care with dedicated staff specializing in minimally invasive cancer treatments, such as tumor ablation and embolization, which are guided by imaging techniques. Their focus on patient-centric care and shorter recovery times makes them attractive to patients seeking high-quality, timely services. In addition, advancements in technology and increased demand for outpatient procedures are driving the growth of specialty clinics, as they offer cost-effective and convenient options compared to hospitals. 

Key U.S. Interventional Oncology Company Insights

Leading market players include Koninklijke Philips N.V. and Siemens Healthineers AG, both innovators in X-ray technology. These companies have utilized their technological expertise to secure a strong presence in this growing market. Their strategies emphasize affordability, user-friendly designs, and improved accessibility, ensuring widespread adoption of their advanced imaging solutions.

Recent Developments

• In September 2024, Stryker acquired care.ai, a company offering smart room technology, AI-assisted virtual care workflows, and ambient intelligence solutions. This acquisition enhances Stryker's wirelessly connected medical device portfolio and healthcare IT offerings.

• In July 2024, Techsomed Ltd. launched its BioTrace software suite in the U.S., featuring BioTraceIO Vision and BioTraceIO Precision. Both solutions, which received FDA clearance in the previous year for liver tumor ablation, are expanding patient access to advanced, image-guided ablation technologies.

• In February 2024, Siemens Healthineers and Profound Medical announced a partnership to combine Profound’s TULSA-PRO system with Siemens’ MAGNETOM Free. Max MRI scanner. This partnership aims to deliver an all-encompassing solution for MRI-guided prostate therapy, improving accuracy in the treatment of prostate ailments.

U.S. Interventional Oncology Market Report Scope 

U.S. Interventional Oncology Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. interventional oncology market report based on techniques, procedures, application, end use:

• Technique Outlook (Revenue, USD Million, 2018 - 2030)

  • Ablation Therapies

    • Radiofrequency Ablation (RFA)

    • Microwave Ablation (MWA)

    • Cryoablation

    • Laser Ablation

    • Irreversible Electroporation (IRE)

  • Embolization Therapies

    • Transarterial Chemoembolization (TACE)

    • Transarterial Radioembolization (TARE)

  • Biopsy Techniques

    • Core Needle Biopsy

    • Fine Needle Aspiration (FNA)

  • Targeted Therapy Delivery Systems

    • Drug-Eluting Beads

    • Radioembolization

    • Drug-Eluting Stents

    • Injectable Hydrogels and Nanoparticles

    • Other Targeted Therapy Systems

  • Image-Guided Procedures

    • Ultrasound Guidance

    • CT Scan Guidance

    • MRI Guidance

    • Fluoroscopy Guidance

• Procedure Outlook (Revenue, USD Million, 2018 - 2030)

  • Tumor Ablation

  • Tumor Biopsy

  • Vascular Interventions

  • Palliative Care

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Liver Cancer

  • Lung Cancer

  • Kidney Cancer

  • Prostate Cancer

  • Breast Cancer

  • Other Cancer

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Specialty Clinics

  • Others